Avalo Therapeutics vs Entera Bio
AVTX and ENTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AVTX and ENTX compare
Entera Bio is the larger company, worth 1.3 times as much as Avalo Therapeutics ($538M against $416M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AVTX | ENTX |
|---|---|---|
| Size and price | ||
| Market cap | $416M | $538M |
| Share price | $7.76 | $3.11 |
| Change, 1 year | −49.7% | 6.9% |
| Change, 5 years | −99.9% | −11.6% |
| Beta (5Y) | 0.87 | 0.62 |
| Employees | 23 | 20 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 1.0× (better) | 2.0× |
| FCF yield | – | −2.9% |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | −61.2% | −35.1% (better) |
| EPS growth, 5Y average | – | −17.9% |
| Profitability | ||
| Return on equity | −33.6% | −20.3% (better) |
| Return on invested capital | – | −193% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 16.63 | 128.41 (better) |
| Altman Z-score | 4.32 | 117.35 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 135% | 6.2% |
| Held by insiders | 0.71% | 11.3% |
| Insider net buying, 12 months | −$8.3M | $141K (better) |
| Short interest, % of float | 16.7% | 4.6% |
Go deeper
- AVTX stock overview
- AVTX income statement
- AVTX valuation and score
- ENTX stock overview
- ENTX income statement
- ENTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.